The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken and failing its intended purpose.
The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid buildup.
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
